JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders

被引：7

作者：

Bellosillo, B ^{[1
]}

Besses, C

Florensa, L

Sole, F

Serrano, S

机构：

[1] Univ Autonoma Barcelona, Univ Pompeu Fabra, Hosp del Mar, Dept Pathol,IMAS, E-08193 Barcelona, Spain

[2] Univ Autonoma Barcelona, Hosp del Mar, IMAS, Dept Clin Hematol, E-08193 Barcelona, Spain

来源：

LEUKEMIA | 2006年 / 20卷 / 04期

关键词：

D O I：

10.1038/sj.leu.2404123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：736 / 737

页数：3

共 9 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2]

FLORENSA L, 1995, LEUKEMIA, V9, P271

[3] The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients [J].

Goerttler, PS ;

Steimle, C ;

März, E ;

Johansson, PL ;

Andreasson, B ;

Griesshammer, M ;

Gisslinger, H ;

Heimpel, H ;

Pahl, HL .

BLOOD, 2005, 106 (08) :2862-2864

[4] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[5] Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].

Jones, AV ;

Kreil, S ;

Zoi, K ;

Waghorn, K ;

Curtis, C ;

Zhang, LY ;

Score, J ;

Seear, R ;

Chase, AJ ;

Grand, FH ;

White, H ;

Zoi, C ;

Loukopoulos, D ;

Terpos, E ;

Vervessou, EC ;

Schultheis, B ;

Emig, M ;

Ernst, T ;

Lengfelder, E ;

Hehlmann, R ;

Hochhaus, A ;

Oscier, D ;

Silver, RT ;

Reiter, A ;

Cross, NCP .

BLOOD, 2005, 106 (06) :2162-2168

[6] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[7] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[8] Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia [J].

Tefferi, A ;

Sirhan, S ;

Lasho, TL ;

Schwager, SM ;

Li, CY ;

Dingli, D ;

Wolanskyj, AP ;

Steensma, DP ;

Mesa, R ;

Gilliland, DG .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :166-171

[9] Identification of an acquired JAK2 mutation in Polycythemia vera [J].

Zhao, RX ;

Xing, S ;

Li, Z ;

Fu, XQ ;

Li, QS ;

Krantz, SB ;

Zhao, ZHJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (24) :22788-22792

← 1 →